Applied DNA Sciences Inc (APDN): Market Cap to Revenue Ratio

Corporate company logo of Applied DNA Sciences Inc (APDN)

Geopolitical tensions are driving demand for DNA tagging, although sanctions may complicate equipment procurement. Analyzing the current price-to-sales ratio on GURU.Markets, we see that 2.20 represents the latest level. The proprietary LinearDNA platform provides Applied DNA Sciences (APDN) with a strong competitive moat. However, the transition to contract RNA synthesis and a liquidity shortage create significant operational risks for the company.

Market Cap to Revenue: adnas.com (APDN) for 07/04/2022 - 10/07/2025

Analytical breakdowns for Applied DNA (APDN)

- stock price and consensus target price:
Share Price adnas.com|APDN - Price Target Chart
- stock exchange capitalization data:
Market Capitalization Applied DNA|APDN - Enterprise Value
- business book valuation details:
Book Value per Share Applied DNA Sciences|APDN - Company Net Assets|Market Value to Book Value adnas.com|APDN - Aggregate Company Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Coefficient Applied DNA Sciences|APDN - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Applied DNA Corp|APDN - Company Aggregate Debts|Debts to Net Assets Applied DNA|APDN - Company Long-Term Debts|Short-Term Debt Applied DNA Sciences|Immediate Liquidity Ratio adnas.com
- company profitability and valuation multiples indicators:
APDN - Net Profit|Future Profit Applied DNA Sciences|APDN - P/E Multiple|Projected Price to Earnings Ratio Applied DNA Sciences Inc|APDN - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Applied DNA|APDN - Operating profit EBITDA|Net earnings per share (EPS TTM) Applied DNA Sciences|APDN - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months adnas.com|APDN - Earnings growth in current year|Projected earnings per share growth rate for next year Applied DNA Sciences
- sales revenue and business income indicators:
APDN - Company Revenue|Company Revenue Forecast adnas.com|APDN - P/S Multiple|Market Cap to Projected Revenue Applied DNA
General company analysis:APDN, adnas.com
Core merchandise of Applied DNA Sciences

For Applied DNA Sciences (APDN), the market valuation relative to the sales volumes of PCR tests and anti-counterfeiting systems reflects investor confidence in the scalability of its genetic technologies. This ratio correlates total market capitalization with annual revenue; therefore, analyzing the price-to-sales trend allows for the identification of an overbought asset and helps avoid entering a position at the peak of speculative optimism.

Competing companies

Tempus AI - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Qiagen QGEN|IONS: Market Cap to Revenue Ratio|Repligen Corp. - P/S Multiple|RNA - P/S Multiple|CRSP (CRISPR Therapeutics AG) - Market Cap to Revenue|genedx.com - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Ultragenyx|Beam Therapeutics Inc (BEAM) - Price-to-Revenue Coefficient|P/S Multiple SRPT|Market Cap to Revenue Twist Bioscience Corp TWST|P/S Multiple TXG (10x Genomics, Inc.)|Price-to-Revenue Coefficient intelliatx.com (NTLA)|Stoke Therapeutics, Inc. - P/S Multiple|Price to Sales BioLife Solutions Inc|Wave Life Sciences Corp (WVE) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio MAZE|SION (Sionna Therapeutics Inc) - P/S Multiple|Market Cap to Revenue primemedicine.com (PRME)|P/S Multiple TSHA|QURE - Price to Sales|Price-to-Revenue Ratio MeiraGTx PLC MGTX|Price-to-Revenue Coefficient REGENXBIO Corp (RGNX)|Solid Biosciences Inc. - P/S Multiple|OCGN - P/S Multiple|PacBio (PACB) - Price-to-Revenue Ratio|Price-to-Sales Ratio BNTC (Benitec Biopharma Inc)|DSGN (Design Pharma) - P/S Multiple|Market Cap to Revenue Ratio RCKT (Rocket Corp)|Price-to-Revenue Ratio 4D Molecular Therapeutics (FDMT)|lexeotx.com - Market Cap to Revenue Ratio|P/S Multiple KRRO (Korro Bio)|EDIT: Market Cap to Revenue Ratio|SLN - Price-to-Revenue Ratio|PRQR (ProQR Therapeutics N.V.) - Market Cap to Revenue Ratio|CDXS: P/S Multiple|sangamo.com (SGMO) - P/S Multiple|NAUT (Nautilus Biotechnology, Inc.) - P/S Multiple|P/S Multiple Metagenomi Inc.|Price-to-Revenue Ratio Precision BioSciences, Inc. (DTIL)|GBIO: Price-to-Sales Ratio|Price-to-Revenue Ratio Boundless Bio, Inc. BOLD|XCUR (Exicure Inc.) - Price-to-Sales Ratio|IMNN - Price-to-Revenue Ratio|PHIO: Price-to-Revenue Ratio|MBIO: P/S Multiple|RNAZ - Price-to-Revenue Coefficient|BNGO (Bionano Genomics Inc.) - P/S Multiple|Price to Sales bluebirdbio.com BLUE|P/S Multiple IPA|Omega Therapeutics Inc - Market Cap to Revenue Ratio|Singular Genomics Systems Inc - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio RGLS|Syros Pharmaceuticals - P/S Multiple|TBIO (telesisbio.com) - Market Cap to Revenue Ratio|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio UBX